Edition:
India

Zoetis Inc (ZTS.N)

ZTS.N on New York Stock Exchange

62.72USD
26 Jun 2017
Change (% chg)

$-0.06 (-0.10%)
Prev Close
$62.78
Open
$62.87
Day's High
$62.87
Day's Low
$62.24
Volume
470,912
Avg. Vol
901,750
52-wk High
$63.85
52-wk Low
$45.28

ZTS.N

Chart for ZTS.N

About

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock)... (more)

Overall

Beta: 1.03
Market Cap(Mil.): $30,812.23
Shares Outstanding(Mil.): 490.80
Dividend: 0.10
Yield (%): 0.67

Financials

  ZTS.N Industry Sector
P/E (TTM): 36.50 13.63 17.39
EPS (TTM): 1.72 -- --
ROI: 14.04 -6.95 -5.22
ROE: 61.64 -6.42 -4.48

BRIEF-Zoetis gets grant from Bill & Melinda Gates foundation to develop sustainable livestock production in sub-Saharan Africa

* Will receive $14.4 million grant from Bill & Melinda Gates foundation over next 3 years

08 May 2017

BRIEF-Zoetis Q1 adjusted earnings per share $0.53

* Q1 earnings per share view $0.48 -- Thomson Reuters I/B/E/S

04 May 2017

BRIEF-Zoetis gets European Commission marketing authorization for Cytopoint

* Zoetis receives european commission marketing authorization for Cytopoint® (lokivetmab) Source text for Eikon: Further company coverage:

27 Apr 2017

BRIEF-Zoetis to acquire Nexvet for US$6.72 in Cash Per Share

* Zoetis to acquire Nexvet Biopharma, an innovator in monoclonal antibody therapies for companion animals

13 Apr 2017

BRIEF-Zoetis CEO's 2016 total compensation was $9.5 million

* CEO Juan Ramón Alaix's 2016 total compensation was $9.5 million versus $8.7 million in 2015 Source text:(http://bit.ly/2nRVXcH) Further company coverage:

31 Mar 2017

BRIEF-Zoetis reports Q4 EPS $0.31

* Q4 earnings per share view $0.45 -- Thomson Reuters I/B/E/S

16 Feb 2017

BRIEF-Zoetis receives European commission approval for stronghold plus

* Zoetis receives European commission approval for stronghold plus Source text for Eikon: Further company coverage:

16 Feb 2017

BRIEF-Pershing Square dissolves sole share stake in Zoetis Inc

* Pershing Square Capital Management dissolves sole share stake in Zoetis Inc - SEC filing

15 Feb 2017

More From Around the Web

Competitors

  Price Chg
Merck & Co., Inc. (MRK.N) $65.92 -0.24
Bayer AG (BAYGn.DE) €122.15 --
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €88.70 --
Eli Lilly and Co (LLY.N) $84.28 +0.39

Earnings vs. Estimates